ROMITI, ADRIANA
 Distribuzione geografica
Continente #
NA - Nord America 1.472
EU - Europa 389
AS - Asia 183
AF - Africa 18
SA - Sud America 9
Totale 2.071
Nazione #
US - Stati Uniti d'America 1.455
IT - Italia 132
SE - Svezia 94
IN - India 68
CN - Cina 59
SG - Singapore 43
FI - Finlandia 42
DE - Germania 41
CA - Canada 14
UA - Ucraina 14
FR - Francia 13
TG - Togo 13
GB - Regno Unito 11
IE - Irlanda 10
AR - Argentina 9
BG - Bulgaria 9
JP - Giappone 7
BE - Belgio 6
RO - Romania 4
HU - Ungheria 3
IR - Iran 3
AL - Albania 2
DK - Danimarca 2
MX - Messico 2
NL - Olanda 2
ZA - Sudafrica 2
AT - Austria 1
ES - Italia 1
GL - Groenlandia 1
HK - Hong Kong 1
MA - Marocco 1
MC - Monaco 1
MU - Mauritius 1
PL - Polonia 1
SC - Seychelles 1
TR - Turchia 1
TW - Taiwan 1
Totale 2.071
Città #
Fairfield 238
Chandler 138
Woodbridge 131
Ashburn 115
Seattle 101
Cambridge 87
Houston 85
Wilmington 67
Dearborn 45
Rome 44
Princeton 38
Plano 36
Beijing 35
San Paolo di Civitate 34
Ann Arbor 33
Lawrence 24
San Diego 21
Boston 20
Singapore 20
New York 15
Des Moines 13
Lomé 13
Millbury 13
Ottawa 11
Andover 10
Dublin 10
Fremont 10
Norwalk 10
Federal 9
Helsinki 9
Sofia 9
Brussels 6
Redwood City 6
Bremen 5
Bühl 4
Guangzhou 4
Budapest 3
Hefei 3
Mannheim 3
Paris 3
Rho 3
Tokyo 3
Chengdu 2
Edinburgh 2
Falls Church 2
Florence 2
Fuzhou 2
Indiana 2
Jacksonville 2
Kunming 2
Leawood 2
London 2
Loreto 2
Los Angeles 2
Mexico City 2
Milan 2
Muizenberg 2
Nanchang 2
Nanjing 2
North York 2
Pisa 2
Redmond 2
San Mateo 2
Serra 2
Snohomish 2
Springfield 2
Tirana 2
Acerra 1
Binasco 1
Boardman 1
Bristol 1
Central 1
Changsha 1
Chongqing 1
Clearwater 1
Cordenons 1
Flushing 1
Frankfurt am Main 1
Grafing 1
Grottaferrata 1
Gunzenhausen 1
Hebei 1
Hounslow 1
Istanbul 1
Ivry-sur-seine 1
Jiaxing 1
Jinan 1
Kish 1
Lissone 1
Madrid 1
Monaco 1
Montclair 1
Napoli 1
New Orleans 1
Nuuk 1
Nürnberg 1
Phoenix 1
Provo 1
Pune 1
Rieti 1
Totale 1.570
Nome #
Circulating tumor cells count predicts survival in colorectal cancer patients. 104
Degradation rate of 5-fluorouracil in metastatic colorectal cancer. A new predictive outcome biomarker? 96
Continuous, low-dose capecitabine for patients with recurrent colorectal cancer 89
5-Fluorouracil degradation rate could predict toxicity in stages II-III colorectal cancer patients undergoing adjuvant FOLFOX 84
Current achievements and future perspectives of metronomic chemotherapy 80
Association between proton-pump inhibitors (PPI) and metronomic capecitabine (MCAP) as salvage treatment for patients with advanced gastro-intestinal tumoursa. A randomized phase II study 80
Evaluation of 5-fluorouracil degradation rate and pharmacogenetic profiling to predict toxicity following adjuvant capecitabine 78
Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer 74
Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation. 71
Complete Regression of a Non-small Cell Lung Cancer Choroidal Metastasis with Intravitreal Bevacizumab 71
17) Follow-up of intestinal metaplasia in the stomach: When, how and why. 71
Impact of tumor site on the prognosis of small bowel adenocarcinoma 69
Tackling pancreatic cancer with metronomic chemotherapy 67
Focus on genetic and epigenetic events of colorectal cancer pathogenesis: implications for molecular diagnosis 66
Tumors of ampulla of Vater: A case series and review of chemotherapy options. 65
Study of histopathologic parameters to define the prognosis of stage II colon cancer 63
null 61
Simultaneous intraductal papillary neoplasms of the bile duct and pancreas treated with chemoradiotherapy. 60
Bevacizumab plus chemotherapy in metastatic colorectal cancer patients treated in clinical practice. 59
Combination therapy of high-dose rabeprazole plus metronomic capecitabine in advanced gastrointestinal cancer: a randomized phase II trial 56
PD-0001CAN WE PREDICT TIME TO TUMOR PROGRESSION IN EARLY COLORECTAL CANCER PATIENTS USING CTCS COUNT? 55
null 52
null 46
null 46
null 46
Arterial thrombotic events and acute coronary syndromes with cancer drugs: Are growth factors the missed link? What both cardiologist and oncologist should know about novel angiogenesis inhibitors 45
Tailored Angiogenesis Inhibition in Cancer Therapy: Respecting the Heart to Improve the Net Outcome 43
null 42
null 42
cAn cArdio-vAsculAr toxicity And bmi evAluAtions predict outcomes in pAtients treAted with chemotherApy plus bevAcizumAb for metAstAtic colorectAl cAncer? 41
Phase II study evaluating the activity and toxicity of a biweekly schedale of gemcitabine and paclitaxel in antracycline-pretreated breast cancer 37
Metronomic chemotherapy for cancer treatment: A decade of clinical studies 35
Long-term survival in metastatic pancreatic cancer. A case report and review of the literature 30
Somatostatin receptor subtype 2 A (SSTR2A) and HER2 expression in gastric adenocarcinoma. 27
Profiling the prognosis of gastric cancer patients. Is it worth to correlate the survival with the clinical/pathological and molecular features of gastric cancers? 26
The TYMS-TSER polymorphism is associated with toxicity of low-dose capecitabine in patients with advanced gastrointestinal cancer 21
Gastric mucosa alterations in first-degree relatives of gastric cancer patients 18
Evolving treatments for advanced gastric cancer: appraisal of the survival trend 14
Exploring the Prognostic Role of Microsatellite Instability in Patients With Stage II Colorectal Cancer: A Systematic Review and Meta-Analysis 14
Updated results of a phase II randomized trial with high dose proton pump inhibitors and metronomic capecitabine as salvage treatment for patients with advanced gastrointestinal tumours 11
A rare case of palatin tonsillar metastasis from small cell lung cancer 10
High-doses of proton pump inhibitors in refractory gastro-intestinal cancer: A case series and the state of art 6
Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure 2
Totale 2.173
Categoria #
all - tutte 5.839
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.839


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020567 78 12 5 21 54 91 87 61 60 46 29 23
2020/2021176 14 22 11 8 16 19 7 16 28 14 13 8
2021/2022375 0 14 37 8 42 10 8 40 25 26 83 82
2022/2023488 76 111 26 57 47 59 9 35 32 4 25 7
2023/2024145 9 26 2 5 17 27 1 10 1 21 11 15
2024/20254 4 0 0 0 0 0 0 0 0 0 0 0
Totale 2.173